<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101504991</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36564</journal-id>
<journal-id journal-id-type="nlm-ta">ACS Appl Mater Interfaces</journal-id>
<journal-id journal-id-type="iso-abbrev">ACS Appl Mater Interfaces</journal-id>
<journal-title-group>
<journal-title>ACS applied materials &amp; interfaces</journal-title>
</journal-title-group>
<issn pub-type="ppub">1944-8244</issn>
<issn pub-type="epub">1944-8252</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28045486</article-id>
<article-id pub-id-type="pmc">6035049</article-id>
<article-id pub-id-type="doi">10.1021/acsami.6b10568</article-id>
<article-id pub-id-type="manuscript">NIHMS975471</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mimicking Neuroligin-2 Functions in <italic>β</italic>-cells by Functionalized Nanoparticles as a Novel Approach for Antidiabetic Therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Munder</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Israel</surname>
<given-names>Liron L.</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kahremany</surname>
<given-names>Shirin</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ben-Shabat-Binyamini</surname>
<given-names>Rina</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Charles</given-names>
</name>
<xref ref-type="aff" rid="A3">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kolitz-Domb</surname>
<given-names>Michal</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Viskind</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Levine</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="A4">ζ</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senderowitz</surname>
<given-names>Hanoch</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chessler</surname>
<given-names>Steven</given-names>
</name>
<xref ref-type="aff" rid="A3">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lellouche</surname>
<given-names>Jean-Paul</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="corresp" rid="CR2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gruzman</surname>
<given-names>Arie</given-names>
</name>
<xref ref-type="aff" rid="A1">§</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>§</label>Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan, Israel</aff>
<aff id="A2"><label>‡</label>Nanomaterials Research Center, Institute of Nanotechnology &amp; Advanced Materials (BINA), Bar-Ilan University, Ramat-Gan, Israel</aff>
<aff id="A3"><label>†</label>Division of Endocrinology, Diabetes &amp; Metabolism, Department of Medicine, University of California, Irvine, California, United States</aff>
<aff id="A4"><label>ζ</label>The Scientific Equipment Center, Faculty of Biological Sciences, Bar-Ilan University, Ramat-Gan, Israel</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Arie Gruzman, Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan, 52900, Israel, <email>gruzmaa@biu.ac.il</email></corresp>
<corresp id="CR2"><label>*</label>Jean-Paul Lellouche, Department of Chemistry, Faculty of Exact Sciences and Nanomaterials Research Center, Institute of Nanotechnology &amp; Advanced Materials (BINA), Bar-Ilan University, Ramat-Gan, 52900, Israel, <email>Jean-Paul.M.Lellouche@biu.ac.il</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>18</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>9</volume>
<issue>2</issue>
<fpage>1189</fpage>
<lpage>1206</lpage>
<!--elocation-id from pubmed: 10.1021/acsami.6b10568-->
<abstract id="ABS1">
<p id="P1">Both pancreatic <italic>β</italic>-cell membranes and presynaptic active zones of neurons include in their structures similar protein complexes, which are responsible for mediating the secretion of bioactive molecules. In addition, these membrane-anchored proteins regulate interactions between neurons and guide the formation and maturation of synapses. These proteins include the neuroligins (e.g., NL-2) and their binding partners, the neurexins. The insulin secretion and maturation of <italic>β</italic>-cells is known to depend on their 3-dimensional (3D) arrangement. It was also reported that both insulin secretion and the proliferation rates of <italic>β-</italic>cells increase when cells are co-cultured with clusters of NL-2. Use of full-length NL-2 or even its exocellular domain as potential <italic>β-</italic>cell functional enhancers is limited by the biostability and bioavailability issues common to all protein-based therapeutics. Thus, based on molecular modeling approaches, a short peptide with the potential ability to bind neurexins was derived from the NL-2 sequence. Here, we show that the NL-2-derived peptide conjugates onto innovative functional maghemite (<italic>γ</italic>-Fe<sub>2</sub>O<sub>3</sub>)-based nanoscale composite particles that enhance <italic>β-</italic>cell functions in terms of glucose-stimulated insulin secretion, and protect them under stress conditions. Recruiting the <italic>β-</italic>cells’ “neuron-like” secretory machinery as a target for diabetes treatment use has never been reported before. Such nanoscale composites might therefore provide a unique starting point for designing a novel class of antidiabetic therapeutic agents that possess a unique mechanism of action.</p>
</abstract>
<kwd-group>
<kwd>Neuroligin-2</kwd>
<kwd>Yb(III)-<italic>γ</italic>-Fe<sub>2</sub>O<sub>3</sub> nanoparticles</kwd>
<kwd>INS-1E cells</kwd>
<kwd>insulin secretion</kwd>
<kwd>computer-aided drug design</kwd>
<kwd>bioactive peptides</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>